8-KEarnings & Results

BIOGEN INC. 8-K Report, Financial Results (Jan 12, 2010)

Filed January 12, 2010For Securities:BIIB

Summary

Biogen Idec Inc. filed an 8-K on January 12, 2010, to report preliminary sales figures for its key drug, TYSABRI® (natalizumab), for the full year 2009. The company announced that TYSABRI® achieved approximately $1,059.2 million in sales for the year. This figure is notable as it indicates TYSABRI® has surpassed the $1 billion sales milestone, demonstrating significant market traction and revenue generation potential for the drug. Investors should note that the sales are broken down into approximately $508.5 million from the United States and $550.7 million from international markets. This split highlights a relatively balanced performance between domestic and global sales, suggesting successful market penetration and acceptance across different geographies. The company's performance in 2009, particularly with TYSABRI®, provides a positive indicator for future revenue growth and the drug's continued importance to Biogen Idec's financial health.

Key Highlights

  • 1Biogen Idec announced full-year 2009 sales for TYSABRI® reached approximately $1,059.2 million.
  • 2TYSABRI® has surpassed the $1 billion sales threshold, signifying a major commercial achievement.
  • 3United States sales for TYSABRI® in 2009 were approximately $508.5 million.
  • 4International sales for TYSABRI® in 2009 were approximately $550.7 million.
  • 5Sales performance indicates a strong global demand for TYSABRI®.
  • 6The report provides an early look at a significant revenue driver for the company.

Frequently Asked Questions

This 8-K filing's primary purpose is to report preliminary financial results, specifically the full-year 2009 sales figures for Biogen Idec's drug TYSABRI® (natalizumab), as required by SEC regulations for material events.

Surpassing $1 billion in annual sales is a major commercial milestone for any pharmaceutical product, indicating strong market acceptance, physician adoption, and significant contribution to the company's revenue. It signals TYSABRI®'s success as a blockbuster drug.

The sales figures show a relatively close distribution between the United States ($508.5 million) and the rest of the world ($550.7 million), indicating balanced market performance and successful international expansion for TYSABRI®.

No, this 8-K filing is limited to Item 2.02, which specifically covers Results of Operations and Financial Condition. It only provides preliminary sales figures for TYSABRI® and does not include comprehensive financial statements like a balance sheet or income statement for the full year.